Neuren Pharmaceuticals Limited

ASX (AUD): Neuren Pharmaceuticals Limited (NEU)

Last Price

14.45

Today's Change

+0.44 (3.14%)

Day's Change

14.02 - 14.57

Trading Volume

534,227

Overview

Market Cap

1 Billion

Shares Outstanding

127 Million

Avg Volume

590,945

Avg Price (50 Days)

12.87

Avg Price (200 Days)

16.17

PE Ratio

14.46

EPS

1.00

Earnings Announcement

29-Jan-2025

Previous Close

14.01

Open

14.19

Day's Range

14.02 - 14.57

Year Range

10.9 - 24.25

Trading Volume

535,774

Price Change Highlight

1 Day Change

3.18%

5 Day Change

16.29%

1 Month Change

19.07%

3 Month Change

15.18%

6 Month Change

-29.66%

Ytd Change

18.00%

1 Year Change

-37.83%

3 Year Change

325.15%

5 Year Change

414.41%

10 Year Change

325.15%

Max Change

153.15%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment